Spirometry follow-up in young children with hemato-oncologic diseases

Ori Efrati, Amos Toren, Hadar Duskin, Gal Goldstein, Jeffrey M. Jacobson, Chaim Churi, Daphna Vilozni

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Treatment of hemato-oncologic patients is often associated with severe pulmonary complications. Pulmonary function is routinely evaluated in older children, whereas in young patients, forced spirometry measurements are infrequently performed. Aim: To assess severity of airway disease using forced spirometry measured prior to and after treatment (over 3 years) in hemato-oncologic children aged 3-7 years in comparison to a healthy population. Material/Methods: 42-children (18-males; age 3-7 years old) with hemato-oncologic illnesses participated in the study. Spirometry was performed before the definitive treatment and up-to 3-years thereafter. Values were compared to those of healthy children of corresponding age. Results: Most children (n=38) showed only minor long term airflow impairment (z-scores of FEV1 at last measurement was -0.00 to -0.45 SD). Prior to definitive treatment eight children presented severe airflow limitation (z-score =-1.35±0.72; -1.61±0.66 and -2.49±0.34 for FEV1, FEV0.5; and FEF25-75 respectively). Four of eight children resumed normal pulmonary function; the spirometry values of the other four children further deteriorated, in association with GVHD and development of bronchiolitis obliterans. Conclusions: Our study suggests that it is important to follow spirometry in young children with hemato-oncologic diseases in order to detect these patients, whose condition may have prognostic implications for their treatment.

Original languageEnglish
Pages (from-to)MT28-MT33
JournalMedical Science Monitor
Volume16
Issue number3
StatePublished - Mar 2010

Keywords

  • Acute lymphoblastic leukemia
  • Hodgkin lymphoma
  • Lung function tests
  • Stem cell transplantation
  • Young children

Fingerprint

Dive into the research topics of 'Spirometry follow-up in young children with hemato-oncologic diseases'. Together they form a unique fingerprint.

Cite this